Roundhill Magnificent Seven ETF vs Personalis Inc. Common Stock — how do they compare? Roundhill Magnificent Seven ETF trades at $72.25 (market cap $5.89B), while Personalis Inc. Common Stock trades at $16.14 (market cap $1.69B). The key difference: Roundhill Magnificent Seven ETF is far larger — about 3.5× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is more actively traded (3,817,236 versus 3,080,349). Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 35 Days and Personalis Inc. Common Stock for 0 Days on average.
| MAGS | PSNL | |
|---|---|---|
Market Cap | $5.89B | $1.69B |
Volume | 3,080,349 | 3,817,236 |
Sector | Sector/Thematic | Health |
52-Week High | $74.30 | $18.38 |
52-Week Low | $55.39 | $5.04 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | — | $1.52B |
Signals from Pluang's Aura AI — not financial advice
MAGS, the Roundhill Magnificent Seven ETF, trades at $74.30, up 0.43% on the day, with a bullish technical signal driven by moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech stocks, though it has underperformed the S&P 500 in 2026 with a modest 2% year-to-date gain. Recent news highlights the group's focus on AI growth but notes a potential shift in market leadership away from the concentrated 'Magnificent Seven' theme.
The outlook for MAGS hinges on the continued AI-driven performance of its holdings, but risks include high concentration, valuation concerns, and market rotation. Investor sentiment is mixed, with some analysts advocating for the basket approach while others warn of fragmentation. Upside potential exists if the mega-caps reassert dominance, but diversification pressures pose a headwind.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →